Engflag

Aquavit E

Quick links to important sections

Aquavit E

Aquavit E_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aquavit E

Property Description
Active Ingredient Tocopherol (Alpha-Tocopherol and Beta-Tocopherol)
Form Soft capsule, oral solution (drops)
Pharmacological Class Vitamin Preparation / Antioxidant
General Purpose Corrects Vitamin E Deficiency (Hypovitaminosis E)
Origin Natural (RRR) or Synthetic (all-rac)

What Type of Medicine is Aquavit E?

Aquavit E is a pharmaceutical preparation classified as an essential Vitamin preparation, supplying Tocopherol, the chemical name for Vitamin E. It belongs to the high-level pharmacological class of Antioxidant compounds, providing an essential contribution to cellular defense mechanisms. As a fat-soluble vitamin, Aquavit E primarily serves to prevent or address Hypovitaminosis E (Vitamin E deficiency), a nutritional state where inadequate supply hinders necessary cellular protection. This preparation is positioned to cater to individuals with dietary restrictions or conditions causing malabsorption, requiring reliable supplementation.

Composition and Source of Tocopherol

The active ingredient is Tocopherol, specifically including Alpha-Tocopherol (alpha-Tocopherol) and related isomers like Beta-Tocopherol (beta-Tocopherol). Aquavit E is supplied in forms designed for its lipophilic nature, most commonly as a soft capsule for the oral route or as an oral solution (drops), suspended in an Oil Base to ensure stability and effective assimilation. The Tocopherol source can be either the highly bioavailable Natural form (RRR-alpha-Tocopherol) or the Synthetic form (all-rac-alpha-Tocopherol). The natural form has measurably higher biological activity in the human body compared to the synthetic racemic mixture, a distinction relevant for formulations emphasizing bioavailability.

General Purpose of This Essential Compound

The core purpose of Aquavit E is to stabilize biological membranes by providing Tocopherol, which acts as a crucial Free Radical Scavenger. This mechanism helps neutralize reactive oxygen species, preventing the destructive process of lipid peroxidation within cell structures. By protecting the integrity of essential membrane components, particularly polyunsaturated fatty acids (PUFAs), the compound supports the long-term functional stability of cells throughout the body, supporting normal cellular function in systems susceptible to oxidative stress.

Regulatory References

  1. Antioxidant
  2. Pharmacological studies confirm that the natural form has measurably higher biological activity in the human body compared to the synthetic racemic mixture [Source: PubMed, J. Nutr. 2010]

What side effects are possible with Aquavit E?

Possible Side Effects and Safety Information

This overview summarizes the officially documented adverse effects and high-level safety constraints of Aquavit E (Tocopherol), as established in government regulatory labeling.

Adverse Reaction Scope

Adverse reactions associated with high-dose Tocopherol intake are generally infrequent. Regulatory documents classify non-serious side effects like nausea, diarrhea, stomach cramps, and headache as Rarely occurring. These effects primarily affect the Gastrointestinal and Nervous Systems.

Serious Adverse Reactions and Key Constraints

Serious Adverse Reactions: The primary documented safety concern is the Increased bleeding tendency (Hemorrhage). This risk is specifically associated with prolonged, high-dose exposure (e.g., exceeding 1,000 mg daily) and is the limiting factor for high-level regulatory intake recommendations.

Population-Specific Constraints: Official labeling advises specific caution in patients with pre-existing bleeding disorders or a history of hemorrhagic stroke. High doses of Tocopherol are documented to potentiate the effects of oral anticoagulants, such as Warfarin, which significantly increases the risk of bleeding. The use of this preparation in these situations requires specific regulatory caution.

Regulatory Safety Summary

The safety profile is characterized by dose- and duration-dependent risks. While common side effects are rare, the most critical risk is the potential for hemorrhage linked to prolonged, high-level supplementation, requiring cautious use in individuals with conditions affecting blood coagulation.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Aquavit E (Tocopherol) overdose is based on documented clinical manifestations resulting from the excessive intake of this essential vitamin preparation. The official documented presentations of overdose include gastrointestinal disturbances such as nausea, diarrhea, and abdominal cramps, alongside systemic symptoms like fatigue, headache, and muscle weakness. These manifestations are generally associated with prolonged exposure to very high doses.

The most serious risk explicitly documented in authoritative regulatory sources is the increased potential for bleeding (hemorrhage). This is a life-threatening outcome that includes the risk of major bleeding events and intracranial hemorrhage. This risk is significantly higher in patients concurrently taking anticoagulants (e.g., warfarin), a key population-specific consideration.

Required Emergency Actions

In the event of suspected overdose, regulatory guidance mandates that the Tocopherol treatment must be discontinued immediately. Urgent medical help is required: a doctor must be called immediately if any unusual signs of bleeding or bruising are observed. Management is primarily symptomatic and supportive, and while no specific chemical antidote is documented, clinical monitoring of coagulation parameters, such as the International Normalized Ratio (INR), is required.

Therapeutic Uses of Aquavit E

What Aquavit E Treats: Main Uses and Benefits

The core therapeutic purpose of Aquavit E (Tocopherol) is generally to help manage the severe, symptomatic consequences of Vitamin E Deficiency (Hypovitaminosis E), focusing on supporting function and long-term well-being in specific patient populations.

This medication is used when patients exhibit clinically significant deficiency, often due to poor fat absorption. The medication is commonly applied in addressing symptom clusters related to neuromuscular impairment, hematological issues, and ocular health compromise.

The primary indications for its use include conditions causing chronic fat malabsorption (such as Cystic Fibrosis and Chronic Cholestatic Hepatobiliary Disease), specific genetic disorders like Abetalipoproteinemia, and high-risk states in premature infants.

Quick Fact: Relief for Neuromuscular Strain

Aquavit E contributes to managing symptoms like ataxia (poor coordination), muscle weakness, and peripheral numbness, supporting the maintenance of functional stability during symptomatic periods. It is commonly used when these symptoms of deficiency create noticeable interference with functional stability.

Eligibility and Restrictions for Use

Who Can and Cannot Use Aquavit E?

The population eligibility for Aquavit E (Tocopherol) is defined by official regulatory criteria, focusing on absolute prohibitions and restrictions based on underlying conditions or age.

Absolute Contraindications

Aquavit E is contraindicated for patients with a known history of hypersensitivity to Tocopherol or any of the product’s excipients. Additionally, specific water-soluble formulations are strictly contraindicated for use in preterm newborn infants, as stated in regulatory prescribing information.

Restricted and Conditional Use

Certain populations require caution and close medical oversight:

  • Patients on Oral Anticoagulants: Individuals taking medications like Warfarin must use high-dose Aquavit E with caution, as it may increase the risk of bleeding, necessitating frequent monitoring of the International Normalized Ratio (INR).
  • Hepatic or Renal Impairment: Use requires caution and close monitoring of organ function, as safety data may be limited in these populations.
  • Low Birth Weight Infants: High doses are restricted due to a documented risk of necrotizing enterocolitis.

General Eligibility

Use is established across full-term neonates, children, adolescents, adults, and older adults for the treatment of confirmed Vitamin E Deficiency (Hypovitaminosis E). Use during pregnancy and lactation is generally considered acceptable at Recommended Dietary Allowance (RDA) levels but restricted from exceeding the Tolerable Upper Intake Level (UL).

What should I know about interactions with other medicines?

Aquavit E Interactions with other medicines and products

Interactions with Tocopherol (Vitamin E) are officially documented by regulatory agencies and generally fall into two primary categories: those affecting coagulation and those altering drug exposure.

Pharmacodynamic Interactions: Coagulation Risk

Co-administration of high doses of Tocopherol with Anti-Vitamin K Agents, such as Warfarin, may increase the risk of bleeding or hemorrhage. This is a pharmacodynamic interaction where Tocopherol interferes with Vitamin K-dependent clotting factors, thereby potentiating the effect of the anticoagulant. Patients on these combinations require close monitoring of coagulation function (e.g., INR) as a procedural constraint, especially if they have underlying Vitamin K deficiency.

Exposure-Altering Interactions

Tocopherol absorption is dependent on dietary fat. Therefore, medicines that impair fat absorption, such as the lipase inhibitor Orlistat and bile acid sequestrants like Cholestyramine, are documented to reduce the systemic exposure of Tocopherol. Regulatory information advises potential timing separation (e.g., at least 2 hours apart) for agents like Orlistat to minimize this pharmacokinetic reduction.

Other Documented Interactions

  • Oral Iron Preparations: Tocopherol may impair the absorption or effectiveness of oral iron supplements, with some regulatory sources suggesting separation of administration.
  • Transporter Effects: Specific formulations containing the water-soluble derivative Tocofersolan are documented to inhibit the P-glycoprotein (P-gp) transporter. This may enhance the intestinal absorption of other co-administered lipophilic medicinal products (e.g., certain steroids or antibiotics).

Official Interaction Statements Summary: The regulatory profile for Aquavit E defines constraints based on a clinically significant potentiation of bleeding risk with Anticoagulants and a risk of reduced Tocopherol exposure when combined with fat-absorption inhibiting agents.

Mechanism of Action

Protection via Membrane Antioxidant Defense

The action of Aquavit E (Tocopherol) is defined by a primary chemical defense mechanism and a secondary regulatory function that influences cellular and vascular dynamics. The core mechanism involves Tocopherol, a chain-breaking antioxidant, incorporating itself into the lipid bilayer. It chemically terminates the destructive cycle of lipid peroxidation by donating a hydrogen atom to aggressive peroxyl radicals. This molecular action preserves the structural integrity of Polyunsaturated Fatty Acids (PUFAs), resulting in the stabilization of lipid membranes, particularly in neural and muscular tissues.

Modulation and Mechanistic Constraint

Beyond free radical scavenging, Tocopherol acts as a modulator via inhibition of Protein Kinase C (PKC) activity and downregulation of adhesion molecules like ICAM-1. These non-antioxidant effects collectively influence platelet aggregation and smooth muscle cell proliferation, influencing the modulation of vascular tone and blood fluidity. The compound's biological activity is further governed by the hepatic alpha-Tocopherol Transfer Protein (alpha-TTP), which ensures stereospecific retention of the most active forms, maintaining the molecular action in tissues, while simultaneously imposing a mechanistic constraint on less active isomers.

Dosage and Administration Information

How to use Aquavit E

Aquavit E is a Vitamin E supplement, most commonly available in capsule, tablet, or liquid/solution forms. The specific dosing and administration schedule must be determined by a healthcare provider based on the patient's age, medical condition, and the severity of any deficiency. Dosage should never exceed the amount recommended by a physician.

General Administration Guidelines

Vitamin E is a fat-soluble vitamin, and its absorption is enhanced when taken with food containing fat. For optimal results, oral forms of Aquavit E should be consumed by mouth with a meal or as directed by a healthcare professional.

Dosage Form General Instruction
Capsules/Tablets Swallow whole with water; do not crush or chew unless specifically advised.
Oral Solution/Drops Measure the dose using the provided dropper or a specially marked measuring spoon. The liquid may be taken directly or mixed with food, such as cereal or juice.

Important Considerations

  • Measuring Doses: Use only the dosage device provided with the liquid formulation, as household spoons may not be accurate.
  • Missed Dose: If a dose is missed, take it as soon as remembered. If it is nearly time for the next scheduled dose, skip the missed one and resume the regular schedule. Do not take a double dose to compensate.
  • Interactions: High doses of Vitamin E may increase the risk of bleeding, especially in individuals taking anticoagulant (blood thinner) medications like warfarin or antiplatelet drugs. Disclose all medications and supplements to your physician before starting Aquavit E, and inform your care team if a surgical procedure is scheduled, as supplementation may need to be temporarily discontinued.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aquavit E

Research Evidence for Correcting Deficiency in Malabsorption Syndromes

Aquavit E, which provides the essential nutrient Tocopherol, was studied to evaluate whether it could address the severe depletion of Vitamin E that occurs in individuals who struggle to absorb fats from their diet. This includes people with conditions marked by functional limitations like Cystic Fibrosis and long-term Chronic Cholestasis. Research in this area primarily involved small, controlled Randomized Controlled Trials (RCTs) alongside extensive long-term observational settings that monitored outcomes related to daily functioning.

The studies focused on outcomes related to systemic or functional imbalance, such as the Tocopherol level in the blood. Long-term observational evidence, which was observed in patients receiving replacement therapy, describes patterns related to the maintenance of neurological function or the non-progression of severe nervous system damage. These studies contribute to understanding the role of Tocopherol replacement in these specific deficiency states.

Studies in Rare Genetic Deficiency Disorders

Tocopherol replacement was evaluated in patients with rare genetic disorders such as Abetalipoproteinemia. Research examined the use of high-dose supplementation in these individuals, exploring outcomes related to the non-progression of progressive neurological signs, like gait disturbances and altered reflexes.

Evidence for Use in High-Risk Populations, such as Premature Infants

Research was studied for the use of Aquavit E in high-risk infants, specifically those defined by Very Low Birth Weight (VLBW) or prematurity. The trials reported that the administration of Tocopherol was associated with the measured elevation of the Tocopherol concentration in the infants' blood. However, findings across different trials regarding the prevention of specific severe neonatal complications were mixed, and evidence quality varies across studies.

Long-Term Evidence and Follow-Up in Clinical Trials

There is limited information for long-term outcomes derived from very large, highly controlled, prospective trials. Long-term patient records data show patterns related to functional stability when replacement therapy is initiated and maintained. The full non-progression of neurological changes over decades is not fully characterized by prospective clinical trials.

Evidence Gaps and Research Uncertainties

Evidence related to Tocopherol replacement for deficiency is highly consistent across studies, but comparative evidence is sometimes lacking, and the data for certain groups remain insufficient. The main limitations across the evidence base include the modest sample sizes used in trials for rare disorders. The evidence related to the absolute long-term outcomes for every potential complication is still emerging.

Frequently Asked Questions (FAQ)

Common questions about Aquavit E (FAQ)

Q: Is Aquavit E meant to be a daily supplement?

A: Official information describes Aquavit E as a pharmaceutical preparation indicated for the treatment of confirmed Vitamin E deficiency. This suggests its use is primarily therapeutic to address a specific medical need, rather than being a general, routine daily supplement.

Q: Does alcohol consumption have an interaction with Aquavit E?

A: Regulatory-derived sources indicate that it is unknown if drinking alcohol will affect how vitamin E supplements like Aquavit E work in the body. A healthcare professional is the appropriate source for information regarding alcohol consumption while using any medication.

Q: Can people with liver issues use Aquavit E?

A: Official documents state that this product should be used with caution in patients who have pre-existing liver impairment. Regulatory constraints indicate that use for individuals with liver impairment may involve close monitoring of liver function tests.

Q: What happens if someone accidentally takes too much Aquavit E?

A: Taking very high doses for prolonged periods is officially documented to increase the risk of serious events, particularly an increased bleeding tendency. In the event of an accidental overdose, the documented procedure is that symptomatic treatment should be provided by a healthcare professional.

Q: What should a patient do if they experience a severe headache while taking Aquavit E?

A: While headaches are listed as a possible rare side effect, a sudden, severe headache is listed in regulatory information as a symptom that may require immediate contact with a healthcare professional. For any severe symptom, consulting a healthcare professional is the appropriate action.

Q: Is Aquavit E the same as over-the-counter vitamin E supplements?

A: Aquavit E is defined as a pharmaceutical preparation that contains a specific, water-soluble derivative of vitamin E (Tocofersolan). This specialized form is designed to treat specific clinical deficiencies, especially in individuals with malabsorption issues, distinguishing it from general non-prescription supplements.

Q: What are the signs of a possible allergic reaction to Aquavit E?

A: Signs of a possible allergic reaction that may require medical attention are listed in regulatory documents. These include symptoms such as rash, hives, difficulty breathing or swallowing, swelling of the mouth, face, or throat, and wheezing.

Q: Can taking Aquavit E affect the absorption of other vitamins or minerals?

A: The formulation of Aquavit E (Tocofersolan) is documented to enhance the absorption of other fat-soluble vitamins. In addition, high levels of Tocopherol are known to impact the function of Vitamin K in the body.

Q: Is Aquavit E generally considered safe for use in children?

A: Official product information states that Aquavit E is indicated for the treatment of vitamin E deficiency due to malabsorption in pediatric patients. This applies to full-term newborns up to 18 years of age.

Q: Is Aquavit E suitable for individuals who have diabetes?

A: Regulatory-derived information indicates that individuals who have diabetes may require discussion with a healthcare professional before starting this product.

Q: What is the source of the active ingredient in Aquavit E?

A: The active ingredient is Tocopherol, a form of Vitamin E naturally found in plant seed oils. The specific ingredient in the pharmaceutical product, Tocofersolan, is a chemically derived form used to maximize absorption.

Q: Why do official documents emphasize a certain group should not use Aquavit E?

A: The emphasis on restrictions for certain groups is based on documented safety risks. For example, official documents advise against use in low birth weight infants due to a recorded risk of developing a severe complication known as necrotizing enterocolitis.

Q: What kind of monitoring might a doctor recommend while taking Aquavit E?

A: The type of monitoring depends on the patient's existing conditions. For individuals taking anticoagulant medicines, coagulation function (INR) monitoring is advised. For patients with pre-existing liver impairment, close monitoring of liver function tests is recommended.

Q: Is the active form of Aquavit E synthetic or natural?

A: The specific pharmaceutical ingredient in Aquavit E, Tocofersolan, is officially described as a synthetic polyethylene glycol derivative. This is a chemically modified version of the naturally occurring d-alpha-tocopherol.

Q: Can Aquavit E be crushed or split if swallowing is difficult?

A: The manufacturer’s instructions advise swallowing the capsules whole. However, the oral solution (drops) form is described as being easily administered directly or mixed with liquid or semi-liquid food, such as milk or cereal, which provides a flexible alternative.

Q: Does Aquavit E affect the results of any standard lab tests?

A: Regulatory documents indicate that when Aquavit E is taken concurrently with anticoagulant medicines, the product may interfere with the results of coagulation tests, such as the International Normalized Ratio (INR).

Q: Does Aquavit E interact with any hormonal medicines or birth control?

A: Studies have examined potential interactions between high doses of Tocopherol and certain hormonal medicines. Regulatory sources advise that products like Aquavit E should be used with caution when taken with hormonal therapies such as Tamoxifen.

Q: Why is Aquavit E sometimes recommended for individuals with malabsorption issues?

A: Aquavit E is recommended for malabsorption because its active ingredient (Tocofersolan) is a water-soluble derivative. This means it is specifically formulated to be absorbed by the body even when the patient lacks the necessary bile salts or fat to properly absorb traditional fat-soluble vitamin E.

Q: Are there known interactions between Aquavit E and herbal supplements?

A: Official information documents that caution is necessary regarding the use of Aquavit E with any herbs or supplements that may lessen blood clotting. This caution is due to the potential for an increased risk of bleeding.

Q: Is it typical for Aquavit E to be taken short-term or long-term?

A: Its use is context-dependent. Regulatory documents indicate that use is typically long-term for individuals dealing with chronic conditions that cause malabsorption, such as chronic cholestasis. For acute or dietary deficiencies, the course of treatment may be short-term.

Q: Does Aquavit E contain any common allergens like gluten or soy?

A: Some formulations of the product are documented to contain excipients such as sodium methyl parahydroxybenzoate (E219) and sodium ethyl parahydroxybenzoate (E215). These specific compounds are documented to potentially cause allergic reactions in sensitive individuals.

Q: Are there different forms of Aquavit E (e.g., liquid, capsule, tablet)?

A: The product is most commonly available as an oral solution (drops), which is suitable for the target patient population. The active ingredient Tocopherol is also generally available in pharmaceutical soft capsule and tablet forms.

How should Aquavit E be stored and disposed of?

How to Store and Dispose of Aquavit E (Tocofersolan)

The storage and disposal instructions for Aquavit E are defined by official regulatory labeling, focusing on container integrity, in-use stability, and child safety.

Official Storage and Stability

Condition Requirement
Unopened Product Does not require any special storage conditions.
Container Rule Must be kept tightly closed.
In-Use Stability Discard 1 month after first opening the bottle.

Handling and Disposal

Aquavit E must be kept out of the sight and reach of children.

For stability, the solution must not be mixed with other medicinal products in the absence of compatibility studies. Unused product and waste material must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aquavit E found in:

A-Z Index: